Dr James L Januzzi
Cardiologist, Massachusetts General Hospital. Prof of Medicine, Harvard Medical School
Dr A Mark Richards
Director, Cardiovascular Research Institute, NUHS, Singapore

Natriuretic Peptides in the Latest ESC & AHA HF Guidelines


  • Natriuretic peptides have a strong rule-out predictive value for Acute Heart Failure and should be used as an initial test. It has Level IA evidence in American and European Cardiology Guidelines for diagnosis and management of heart failure

Transcript of the above video:

NT-proBNP is a class I recommendation in the guidelines for heart failure diagnosis and prognosis in the United States heart failure guidelines.

Natriuretic peptides mentioned actually first in the European Society of Cardiology guidelines on the diagnosis and management of heart failure and these guidelines have just been updated as of May 2016.

So when you look at the section that says diagnosis, the first thing that’s listed is natriuretic peptides. And there’s a large flow diagram, and in the center of that, you have natriuretic peptides. And one of the key recommendations which is given – Level I recommendation and – Level A of evidence to support it – is anybody presenting with breathlessness, suspected of possibly having heart failure, acute heart failure, should have a natriuretic peptide level measured. And it’s described as an important initial test, even if there’s a degree of evidence from other sources, the natriuretic peptides should be measured and it’s confidently stated that this is a strong rule-out test.

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi